TY - JOUR T1 - Characterization of Circular RNA Transcriptomes in Psoriasis and Atopic Dermatitis Reveals Disease-specific Expression Profiles JF - medRxiv DO - 10.1101/2020.05.26.20090019 SP - 2020.05.26.20090019 AU - Liviu Ionut Moldovan AU - Lam Alex Tsoi AU - Stephen Weidinger AU - Johann Gudjonsson AU - Jørgen Kjems AU - Lasse Sommer Kristensen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/27/2020.05.26.20090019.abstract N2 - Background Atopic dermatitis (AD) and psoriasis, two chronic inflammatory skin diseases, affect a large number of individuals worldwide, and are associated with various comorbidities. Circular RNA (circRNA) constitute a major class of non-coding RNAs that have been implicated in many human diseases, although their potential involvement in inflammatory skin diseases remains elusive.Objectives To compare and contrast the circRNA expression landscapes in paired lesional and non-lesional skin from psoriasis and AD patients relative to skin from unaffected individuals. Moreover, to correlate circRNA expression to disease severity.Methods We analyzed high-depth RNA-seq data from paired lesional and non-lesional skin samples from 27 AD patients, 28 psoriasis patients, and 38 healthy controls. CircRNAs and their cognate linear transcripts were quantified using the circRNA detection algorithm, CIRI2.Results We identified 39,286 unique circRNAs in total and found that psoriasis and AD lesional skin could be distinguished from non-lesional and healthy skin based on circRNA expression landscapes. In general, circRNAs were less abundant in lesional relative to non-lesional and healthy skin. Differential expression analyses revealed many significantly downregulated circRNAs, mainly in psoriasis lesional skin, and a strong correlation between psoriasis and AD-related circRNA expression changes was observed. A subset of circRNAs, including ciRS-7, was specifically dysregulated in psoriasis and show promise as biomarkers for discriminating AD from psoriasis.Conclusion Psoriasis and circRNA transcriptomes share expression features, including a global downregulation, but only psoriasis is characterized by several circRNAs being dysregulated independently of their cognate linear transcripts.Competing Interest StatementConflicts of Interest: S.W. is coordinator of the BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) project funded by the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 821511, co-principal investigator of the German Atopic Dermatitis Registry TREATgermany. He has received institutional research grants from Sanofi Genzyme, LEO Pharma, and LOreal, has performed consultancies for Sanofi-Genzyme, Regeneron, LEO Pharma, Pfizer, Abbvie, Novartis, and Kymab, has lectured at educational events sponsored by Sanofi-Genzyme, Regeneron, LEO Pharma, Abbvie and Galderma, and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used e.g. the treatment of psoriasis and atopic dermatitis.Funding StatementThis project has received funding from the European Union Horizon 2020 research and innovation programme under the Marie SkÅ,odowska-Curie grant agreement No 721890.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed written consent was obtained from human subjects under a protocol approved by the local ethics board at the University Hospital Schleswig-Holstein, Kiel, Germany (reference: A100/12)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNational Center for Biotechnology Information Gene Expression Omnibus accession: GSE121212. ER -